Drug Development

Chroma Therapeutics Ltd raised £30 million in a third private round, giving the chromatin specialist funding for the next three years and enabling it to advance the lead programme through Phase II clinical studies and bring two further products into the clinic.

After the initial hype, the long haul through clinical development and the inevitable pitfalls, gene therapy is on the verge of becoming a commercial reality in Europe - ahead of the US.